Zaloguj się

Gotowe bibliografie tematyczne / HIF-PHI

Spis treści

Artykuły w czasopismach

Gotowa bibliografia na temat „HIF-PHI”

Autor: Grafiati

Data publikacji: 2 czerwca 2025

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „HIF-PHI”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "HIF-PHI"

1

Takahashi, Akira. "Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors." Nutrients 16, no. 4 (2024): 520. http://dx.doi.org/10.3390/nu16040520.

Pełny tekst źródła

Streszczenie:

Since zinc is involved in many aspects of the hematopoietic process, zinc supplementation can reduce erythropoiesis-stimulating agents (ESAs) in patients undergoing hemodialysis. However, it remains unclear whether hypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs) have similar reduction effects. HIF-PHI stabilizes HIF, which promotes hematopoiesis, although HIF-1α levels are downregulated by zinc. This study aimed to investigate the effect of zinc supplementation on the hematopoietic effect of HIF-PHI in patients undergoing hemodialysis. Thirty patients undergoing maintenance h

Style APA, Harvard, Vancouver, ISO itp.

2

Yoshida, Yukina, Tomoaki Takata, Sosuke Taniguchi, et al. "Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease." Biomedicines 12, no. 12 (2024): 2926. https://doi.org/10.3390/biomedicines12122926.

Pełny tekst źródła

Streszczenie:

Background/Objectives: Renal anemia is one of the major complications associated with chronic kidney disease (CKD). Erythropoietin-stimulating agents (ESAs) are commonly used; however, some patients exhibit resistance. Hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) have emerged as a novel treatment for renal anemia, enhancing erythropoiesis and iron metabolism. Methods: We retrospectively analyzed laboratory data related to erythropoiesis from 105 patients with CKD before and after treatment with HIF-PHI or ESA. The dialysis initiation and mortality rates were also assessed

Style APA, Harvard, Vancouver, ISO itp.

3

Koukourakis, M. I., A. Giatromanolaki, E. Sivridis, et al. "Intratumoral lactate dehydrogenase 5 (LDH5) protein expression is associated with expression of angiogenesis markers and hypoxia in patients with colorectal cancer (CRC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4107. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4107.

Pełny tekst źródła

Streszczenie:

4107 Background: Recent clinical trials (CONFIRM 1 and CONFIRM 2) have shown that metastatic CRC patients (pts) with high serum lactate dehydrogenase (LDH) derive the greatest therapeutic benefit from PTK787/ZK 222584 (PTK/ZK). PTK/ZK is a novel, oral tyrosine kinase inhibitor (TKI), which blocks all known VEGF receptors (VEGFR). From previous studies, total LDH and isoenzyme LDH5 have been associated with tumor aggressiveness and hypoxia. In the present study, we tested whether CRC pts with high levels of tumor LDH5 have increased expression of proteins involved with hypoxia (hypoxia inducibl

Style APA, Harvard, Vancouver, ISO itp.

4

Schröppel, Bernd. "HIF-PH-Inhibitoren in der Therapie der renalen Anämie." Dialyse aktuell 26, no. 10 (2022): 453–59. http://dx.doi.org/10.1055/a-1924-3492.

Pełny tekst źródła

Streszczenie:

ZUSAMMENFASSUNGDie bisherige Standardbehandlung der renalen Anämie umfasst die Sicherstellung ausreichender Eisenspeicher und die Verabreichung von Erythropoetin-Stimulanzien (ESA). Eine medikamentöse Alternative zu ESA sind nun Wirkstoffe, die HIF-PH (HIF: Hypoxie induzierbarer Faktor; PH: Prolylhydroxylasen) inhibieren. Denn Prolylhydroxylasen vermitteln den sauerstoffabhängigen Abbau von HIF und regulieren so die zelluläre Antwort auf Hypoxie in der Anämie und eine Reihe anderer chronischer Erkrankungen. HIF-PH-Inibitoren (HIF-PHI) sind eine neue Klasse oraler Medikamente, die HIF aktiviere

Style APA, Harvard, Vancouver, ISO itp.

5

Cabral Filho, Lauro Wilson Lima Ferro, Wendell de Jesus Nunes Barbosa, Patrícia Uchõa Leitão Cabral, and Yúla Pires da Silveira Fontenele de Meneses. "Inibidores da enzima prolil hidroxilase induzida por hipóxia na saúde e no desempenho desportivo." Lecturas: Educación Física y Deportes 26, no. 277 (2021): 190–201. http://dx.doi.org/10.46642/efd.v26i277.2465.

Pełny tekst źródła

Streszczenie:

Os inibidores da enzima prolil hidroxilase induzida por hipóxia (HIF-PHI) é um agente terapêutico sob uma nova classe de fármacos que estimulam a resposta do corpo à hipóxia sem alterar a pressão parcial de oxigênio nos tecidos, o que suprime e induz os genes responsáveis ao processo hematopoiético. Esses agentes estimulantes de eritropoiese podem influenciar a saúde humana possibilitando novas oportunidades no tratamento de anemia com doença renal crônica, no entanto, os mesmos têm também chamando a atenção de atletas que buscam a melhoria da performance. O objetivo deste estudo foi descrever

Style APA, Harvard, Vancouver, ISO itp.

6

Hara, Ryujiro, Toshihiko Kitahara, Hiroki Numata, et al. "Daprodustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, Improves Hematological Insufficiency without Progression of Myelodysplastic Syndrome with Chronic Kidney Disease." Blood 142, Supplement 1 (2023): 6495. http://dx.doi.org/10.1182/blood-2023-182991.

Pełny tekst źródła

Streszczenie:

Introduction Hematological insufficiency is a critical issue in the treatment of myelodysplastic syndrome (MDS). The current standard treatment for cytopenia in MDS involves blood transfusion and the administration of erythropoiesis stimulating agents (ESAs). However, ESAs are only effective in certain patients with low erythropoietin levels; patients who are not suitable candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT) require lifelong blood transfusions. As a result, there is a growing demand for new treatments for cytopenia in MDS, and researchers have been expl

Style APA, Harvard, Vancouver, ISO itp.

7

Qian, Fang-Yuan, Zuo-Lin Li, Yu-Dong Guo, et al. "Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease." American Journal of Physiology-Renal Physiology 317, no. 5 (2019): F1265—F1273. http://dx.doi.org/10.1152/ajprenal.00260.2019.

Pełny tekst źródła

Streszczenie:

Muscle wasting and diminished physical performance contribute to the morbidity and mortality of chronic kidney disease (CKD), for which no curative therapy exists. Accumulating evidence indicates that impaired angiogenesis occurs in the muscles of CKD models. Therefore, proangiogenesis therapy is considered a potentially effective strategy for limiting CKD-associated myopathy. Hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor (HIF-PHI) stabilizes HIF and enhances muscle angiogenesis during acute ischemia; however, little evidence was available from CKD models. Here, we assessed wheth

Style APA, Harvard, Vancouver, ISO itp.

8

Shimoda, Larissa A., Michele Fallon, Sarah Pisarcik, Jian Wang, and Gregg L. Semenza. "HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes." American Journal of Physiology-Lung Cellular and Molecular Physiology 291, no. 5 (2006): L941—L949. http://dx.doi.org/10.1152/ajplung.00528.2005.

Pełny tekst źródła

Streszczenie:

Vascular remodeling resulting from altered pulmonary arterial smooth muscle cell (PASMC) growth is a contributing factor to the pathogenesis of hypoxic pulmonary hypertension. PASMC growth requires an alkaline shift in intracellular pH (pHi) and we previously showed that PASMCs isolated from mice exposed to chronic hypoxia exhibited increased Na+/H+ exchanger (NHE) expression and activity, which resulted in increased pHi. However, the mechanism by which hypoxia caused these changes was unknown. In this study we tested the hypothesis that hypoxia-induced changes in PASMC pH homeostasis are medi

Style APA, Harvard, Vancouver, ISO itp.

9

Wu, Henry H. L., Rajkumar Chinnadurai, and Robert J. Walker. "Is HIF-PHI the Answer to Tackle ESA Hyporesponsiveness in the Elderly?" Kidney and Dialysis 2, no. 3 (2022): 446–53. http://dx.doi.org/10.3390/kidneydial2030040.

Pełny tekst źródła

Streszczenie:

Anemia in chronic kidney disease (CKD) has become an important clinical issue with the increased prevalence of elderly patients living with CKD progressing to kidney failure. The causes of anemia in elderly individuals tend to be multifactorial, exacerbated by the physiological effects of aging, frailty and declining kidney function. Erythropoiesis-stimulating agents (ESAs) are the conventional therapeutic option for anemia in CKD. However, ESA hyporesponsiveness is a commonly observed issue in clinical practice and an issue that is more challenging to resolve in elderly patients living with f

Style APA, Harvard, Vancouver, ISO itp.

10

Ogawa, Chie, Ken Tsuchiya, and Kunimi Maeda. "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism." International Journal of Molecular Sciences 24, no. 3 (2023): 3037. http://dx.doi.org/10.3390/ijms24033037.

Pełny tekst źródła

Streszczenie:

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of EPO transcription, but HIF1α and 3α also may have additional influences on erythroid maturation. HIF is also involved in the regulation of iron, an essential component in erythropoiesis. Iron is essential for the organism but is also highly toxic, so its absorption and retention are strictly controlled. HIF also induces the synthesis of proteins involved in iron regulation, thereby ensuring the availability of iron

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!